Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer
For patients with EGFR PACC-mutated non-small cell lung cancer (NSCLC), the targeted therapy firmonertinib achieved durable antitumor activity in a Phase Ib trial led by researchers at The University of Texas MD Anderson Cancer Center, supporting an approach to selecting treatments based on the structural features of uncommon EGFR mutations.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Study finds differences in cellular responses to exercise
United Kingdom
-
AI detects coronary heart disease from face and tongue photos in small test
United Kingdom
-
Treating depression during pregnancy may benefit baby's brain development—new research
United Kingdom
-
'Highly sensitive' people may not experience everything more intensely, study suggests
United Kingdom
-
The receptor behind chili-pepper burn may hold clues to pain treatments
United Kingdom
-
Drape Some of This ‘Plant Armor’ Fabric Over a Strawberry Patch to Triple Yields with Less Pesticides
United Kingdom
-
Black children at risk for severe form of asthma, new research shows
United Kingdom
-
Vaccines have been so successful that some people have forgotten why we need them
United Kingdom